Overcoming the Challenges of Immuno-Oncology Biomarker Discovery: From Sample to Analytics, New Webinar Hosted by Xtalks

Xtalks Life Science Webinars

In this webinar, featured speaker Erin Newburn, Associate Director and Field Applications Scientist from Personalis, Inc. will discuss how a combined whole exome and transcriptome platform such as ACE ImmunoID™ can help to overcome obstacles of immuno-oncology biomarker discovery.

Topics include:

  • Generating high-quality data when working with limited sample material or degraded or archival specimens
  • Decreasing the risk of missing potential targets with comprehensive assays
  • Going beyond PD-L1 and TMB to complex immuno-oncology biomarkers and signatures

Only 20% of patients respond to cancer immunotherapies and determining which patients will respond to which treatment options rely on the identification of predictive biomarkers.

Immuno-oncology biomarkers such as tumor mutational burden (TMB) or PD-L1 expression are promising but have demonstrated limited predictive utility. Identifying more robust predictors of patient response to cancer immunotherapy may depend on finding the right combination of biomarkers—but few platforms support multi-dimensional biomarker analysis.

Personalis ACE ImmunoID™ is a combined whole exome and transcriptome platform, with analytics that elucidates the tumor and its microenvironment to accelerate biomarker discovery. The platform is based on Personalis’ patented Accuracy and Content Enhanced (ACE) Technology, which features augmentation of sequencing gaps in regions missed by standard exome assays, ensuring more comprehensive variant capture (SNVs, indels, fusions).

The live broadcast takes place on Monday, April 30, 2018, at 1 p.m. EDT and will benefit professionals from biopharmaceutical organizations with immuno-oncology pipelines, including those working on immuno-oncology clinical development, biomarkers, translational research, personalized medicine, neoantigen-based therapeutics, checkpoint inhibitors and immune modulators.

For more information about this complimentary session visit: Overcoming the Challenges of Immuno-Oncology Biomarker Discovery: From Sample to Analytics.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical and biotech companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Contact:

Nima Rajan

Tel: +1 (416) 977-6555 ext 352

Email: nrajan@xtalks.com

Source: Xtalks


Categories: Pharmaceuticals and Biotech, Cancer/Oncology, Diagnostics, Healthcare and Medical Informatics

Tags: biomarker, checkpoint inhibitors, immune modulators, immuno-oncology, neoantigen-based therapeutics, Personalis, personalized medicine, translational research, Xtalks


Additional Images

About Xtalks

View Website

Xtalks is a leading provider of educational webinars to the global life science, food and medical device community.